Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told
Nektar Therapeutics claims Eli Lilly & Co. may owe it nearly $1 billion in damages for allegedly breaching their Rezpeg deal, according to testimony in a California federal court. The amount is based on Nektar's expert's calculation of lost profits and other factors.
How this was made
The 30-second read
Why it matters
The disclosed potential liability introduces new risk for Lilly and a possible upside for Nektar.
Market read
First reporting of a major legal claim that could affect stock prices of both parties.
What to watch
Insurance coverage and potential counterclaims could mitigate the exposure.
Background
A California federal jury heard testimony from Nektar's damages expert regarding a breach of a deal with Eli Lilly.
Ticker impact
Eli Lilly could be ordered to pay nearly $1 billion to Nektar Therapeutics if a breach is found.
downside pressure on LLY
Large financial exposure disclosed for the first time.
Nektar Therapeutics' damages expert testified that Lilly may owe $1 billion for a breached deal.
upside potential for NKTR
First report of a sizable claim against a major pharma partner.
Market effects
Legal risk considerations for pharma sector.
U.S. biotech market may see heightened volatility.
Potential ripple effect on biotech valuations worldwide.
Counterpoint
The claim may be overstated; settlement could be lower or dismissed.
Key entities
- CompanyEli Lilly & Co.
Pharmaceutical giant potentially liable for $1B.
- CompanyNektar Therapeutics
Biotech firm seeking damages from Lilly.
